Sign Up for a Free Account
  • Updated 03.02.2023
  • Released 11.11.1996
  • Expires For CME 03.02.2026

Medium-chain acyl-CoA dehydrogenase deficiency



Medium-chain acyl-CoA dehydrogenase deficiency is the most common inborn error of metabolism in the United States Caucasian population. Diagnosed symptomatically, the morbidity and mortality are high, but outcome is significantly improved if patients are identified before the onset of symptoms. It is now included on newborn screening in the United States and in many other developed nations. The author highlights the technologies that have made it possible to diagnose this condition in the newborn period in a cost-effective fashion. As a result, more patients will ultimately find their way into adult medicine and neurology clinics in the coming years.

Key points

• Medium-chain acyl-CoA dehydrogenase deficiency is now reliably identified in newborn screening in all states in the U.S. and many countries.

• Treatment during acute illnesses consists of maintaining caloric intake with sugar-containing oral or parenteral fluids.

• Carnitine is rarely, if ever, needed to treat medium-chain acyl-CoA dehydrogenase deficiency.

Historical note and terminology

Medium-chain acyl-CoA dehydrogenase deficiency is an autosomal recessive inborn error of mitochondrial fatty acid beta-oxidation (15). The disorder was not identified until the early 1980s (50) but is now recognized as the most common of the genetic defects in fatty acid oxidation (05). It is the most frequent inborn error of metabolism in Caucasians, especially those of Western European descent. The medical literature prior to 1980 contains a number of references to patients who either were later proven to have medium-chain acyl-CoA dehydrogenase deficiency or probably had this disorder. The possibility of medium-chain acyl-CoA dehydrogenase deficiency should be considered in this older literature in patients described as having dicarboxylic aciduria, infantile Reye syndrome, and, particularly, either "systemic carnitine deficiency" or "primary carnitine deficiency." For example, four patients originally published as having "primary systemic carnitine deficiency" were later shown to have medium-chain acyl-CoA dehydrogenase deficiency (12). The reason for this confusion is that medium-chain acyl-CoA dehydrogenase deficiency and several other genetic defects in acyl-CoA oxidation are associated with secondary carnitine deficiency. Caution must be taken in reviewing discussions of carnitine deficiency that were published between 1970 and 1982 because they can be outdated and can be misleading.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

  • Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660



ISSN: 2831-9125